Asterias Biotherapeutics (AST) Reports In-Line Q4 EPS

Asterias Biotherapeutics (NYSE: AST) reported Q4 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $608 thousand versus the consensus estimate of $1.07 million.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• NRC Health (NRC) Reiterated at Market Outperform by Citizens Ahead of Annual Forum
• Jefferies Financial Group (JEF) Misses Q2 EPS by 22c